Study of pralsetinib or anlotinib for advanced medullary thyroid cancer with RET gene changes
Part of Cancer clinical trials.
This study tests two drugs, pralsetinib and anlotinib, in people whose medullary thyroid cancer has spread or cannot be removed with surgery and has a specific change in the RET gene. The goal is to see how well these drugs work and how safe they are.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have medullary thyroid cancer (MTC) confirmed by a biopsy.
- Your cancer must be locally advanced or have spread to other parts of the body, and you need treatment.
- Your cancer must have gotten worse in the last 14 months.
- You must have a change (mutation) in the RET gene found in your tumor or blood.
- You cannot have taken pralsetinib, anlotinib, cabozantinib, or vandetanib before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies anlotinib in people with advanced or metastatic medullary thyroid cancer that has been getting worse. It aims to see how well the treatment controls the cancer and how safe it is for patients who can’t have curative surgery.
This trial tests how pralsetinib interacts with other drugs in people with advanced solid tumors that have a specific RET gene change. It aims to find the right dose and safety profile.
This trial tests a combination of two drugs, anlotinib (a targeted therapy) and benmelstobart (an immunotherapy), for people with differentiated thyroid cancer that has spread or cannot be removed. It may be an option if your cancer did not respond to or got worse after first treatment.
This trial tests a targeted therapy pill (anlotinib) for people with advanced thyroid cancer that stopped responding to radioactive iodine. It may slow tumor growth or shrink tumors.
This trial tests whether giving targeted drugs before surgery can shrink advanced thyroid cancers that are hard to remove. It uses genetic test results to match you to a specific treatment arm, aiming to make surgery safer and more successful.
This trial tests if an existing drug (used for other conditions) can help people with advanced thyroid cancer who have run out of treatment options. You'll get a new drug and be monitored to see if it shrinks your cancer or slows it down.
Hear when a new Medullary Thyroid Cancer (MTC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.